A subscription to JoVE is required to view this content. Sign in or start your free trial.
This protocol describes the generation of murine orthotopic bladder tumors in female C57BL/6J mice and the monitoring of tumor growth.
This protocol describes the generation of bladder tumors in female C57BL/6J mice using the murine bladder cancer cell line MB49, which has been modified to secrete human Prostate Specific Antigen (PSA), and the procedure for the confirmation of tumor implantation. In brief, mice are anesthetized using injectable drugs and are made to lay in the dorsal position. Urine is vacated from the bladder and 50 µL of poly-L-lysine (PLL) is slowly instilled at a rate of 10 µL/20 s using a 24 G IV catheter. It is left in the bladder for 20 min by stoppering the catheter. The catheter is removed and PLL is vacated by gentle pressure on the bladder. This is followed by instillation of the murine bladder cancer cell line (1 x 105 cells/50 µL) at a rate of 10 µL/20 s. The catheter is stoppered to prevent premature evacuation. After 1 h, the mice are revived with a reversal drug, and the bladder is vacated. The slow instillation rate is important, as it reduces vesico-ureteral reflux, which can cause tumors to occur in the upper urinary tract and in the kidneys. The cell line should be well re-suspended to reduce clumping of cells, as this can lead to uneven tumor sizes after implantation.
This technique induces tumors with high efficiency. Tumor growth is monitored by urinary PSA secretion. PSA marker monitoring is more reliable than ultrasound or fluorescence imaging for the detection of the presence of tumors in the bladder. Tumors in mice generally reach a maximum size that negatively impacts health by about 3 - 4 weeks if left untreated. By monitoring tumor growth, it is possible to differentiate mice that were cured from those that were not successfully implanted with tumors. With only end-point analysis, the latter may be mistakenly assumed to have been cured by therapy.
The goal of this method is to generate murine orthotopic bladder tumors and to monitor the implanted tumors as accurately as possible, so that mice without tumor implantation are not thought to have been cured at end-point analysis. Overall, the method shown will reduce the need for large numbers of mice for experimental analysis and ensure greater accuracy in determining therapeutic outcomes.
The development of an orthotopic model for cancer is important, as implanting tumor cells subcutaneously does not recapitulate the environment of the clinical disease or enable the development of therapeutic strategies. The architecture of the bladder....
All animal work adhered to the Institutional Animal Care and Use Committee (IACUC) guidelines on animal use and handling (Protocol number 084/12) at the National University of Singapore.
1. Growing MB49-PSA Cells In Vitro and Measuring PSA Secretion
PSA secretion from MB49 cells was found to vary with the growth media. MB49-PSA is grown in DMEM media because this results in increased PSA secretion (Figure 1A). In order to determine the sensitivity of the PSA ELISA and real-time PCR, different numbers of MB49-PSA-secreting cells were mixed with MB49 parental cells. PSA ELISA detects a minimum of 1 x 105 PSA-secreting cells/1 x 106 cells (Figure 1B), while real-time PCR analysis d.......
The most critical steps in the protocol are 1) successfully maintaining the tumorigenicity of the cell line; 2) ensuring measurable PSA secretion before tumor cell implantation in mice; 3) generating a single-cell suspension for implantation so as to reduce variation in tumor size; and 4) instilling cells at a slow rate to prevent vesico-ureteral reflux, resulting in tumor cell implantation in the kidney.
After prolonged passage in vitro, MB49/MB49-PSA cells can lose their tumorigenic.......
This work was funded by a grant from the National Medical Research Council of Singapore (NMRC/CIRG/1335/2012) awarded to Professor Kesavan Esuvaranathan.
....Name | Company | Catalog Number | Comments |
MB49-PSA cells | N/A | N/A | ref (Wu QH, 2004) |
RPMI 1640 media | HyClone | SH30027.01 | |
Dulbecco's Modified Eagle's Medium (DMEM) media | Biowest | L0102 | |
Fetal Bovine Serum (FBS) South American | Biowest | S1810 | |
Fetal Bovine Serum (FBS) South American, Premium | Biowest | S181B | |
Fetal Bovine Serum (FBS) | HyClone | SH30088.03 | |
L-glutamine | Biowest | X0550 | |
Penicillin-Streptomycin | Biowest | L0022 | |
Hygromycin B | Invitrogen | 10687-010 | |
free PSA (Human) ELISA kit | Abnova | KA0209 | |
TRIzol Reagent for RNA extraction | Ambion | 15596026 | |
High Capacity cDNA Reverse Transcription Kit with RNase Inhibitor | Applied Biosystems | 4374967 | |
TaqMan Universal PCR Master Mix | Applied Biosystems | 4304437 | |
TaqMan Gene Expression Assay – Mouse Actb | Applied Biosystems | 4331182 | Mm00607939_s1 |
TaqMan Gene Expression Assay – Human KLK3 | Applied Biosystems | 4331182 | Hs00426859_g1 |
C57BL/6J female mice | In Vivos | 4-6 wk old | |
Anesthesia (75mg/kg Ketamine and 1mg/kg Medetomidine) | Local pharmacy | ||
Reversal drug (1mg/kg Atipamezole) | Local pharmacy | ||
Ear punch | Electron Microscopy Sciences | 72893-01 | |
Hartmann's solution or Compound sodium lactate | B Braun | ||
Ophthalmic ointment - Duratears sterile ocular lubricant ointment | Alcon | ||
Heat pack - HotHands handwarmers | Heatmax Inc | ||
Introcan Certo IV catheter | B Braun | 4251300 | 24G x 3/4″ |
Aquagel Lubricating jelly | Local pharmacy | ||
Poly-L-lysine solution, 0.01%, | Sigma | P4707 | |
cOmplete, Mini, EDTA-free Protease Inhibitor Cocktail | Roche | 4693159001 | |
Quantichrom Creatinine Assay Kit | BioAssay Systems | DICT-50 | |
Fluorescent dye - VivoTrack 680 | Perkin Elmer | NEV12000 | |
RNAlater-ICE Frozen Tissue Transition Solution | Ambion | 4427575 | |
Name | Company | Catalog number | Comments |
Equipment and Software | |||
7500 Realtime PCR System | Applied Biosystems | ||
7500 Software v2.3 | Applied Biosystems | ||
Metabolic Cage | Tecniplast | Vertical type rack for 12 cages | |
BD FACSCanto I system | BD Biosciences | ||
BD FACSDiva software v7 | BD Biosciences | ||
IVIS SpectrumCT in vivo imaging system | Caliper Life Sciences | ||
Living Image Software v3.1 | Caliper Life Sciences | ||
Vevo 2100 imaging system | VisualSonics |
This article has been published
Video Coming Soon
ABOUT JoVE
Copyright © 2025 MyJoVE Corporation. All rights reserved